ReviewCost effectiveness and resource allocation : C/E2018
Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings.
Review in Cost effectiveness and resource allocation : C/E, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review.PharmacoEconomics · 2020Pooled it
- A Technology Selection Tool Applying Multiple Criteria Decision Analysis for Virtual Care Implementation.Mayo Clinic proceedings. Digital health · 2025Article
- Beyond cost-effectiveness: a reflective commentary on adapting global health technology assessment for equity considerations in South Africa and other LMICs.International journal for equity in health · 2025Article
- The need for a broad perspective when assessing value-for-money for out-of-hours primary care.Primary health care research & development · 2024Review
- National Immunization Program Decision Making Using the CAPACITI Decision-Support Tool: User Feedback from Indonesia and Ethiopia.Vaccines · 2024Article
- The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review.Frontiers in pharmacology · 2024Review
- Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?Orphanet journal of rare diseases · 2022Review
- Priority setting of vaccine introduction in Bangladesh: a multicriteria decision analysis study.BMJ open · 2022Article
- Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting.Clinical drug investigation · 2022Review
- Assessing the potential of HTA to inform resource allocation decisions in low-income settings: The case of Malawi.Frontiers in public health · 2022Article
- A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.PharmacoEconomics - open · 2020Article
- Malaria Risk Map Using Spatial Multi-Criteria Decision Analysis along Yunnan Border During the Pre-elimination Period.The American journal of tropical medicine and hygiene · 2020Article
- Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review.PharmacoEconomics - open · 2020Review
- 'It takes two to tango': Bridging the gap between country need and vaccine product innovation.PloS one · 2020Article
- Article
- Introduction: priority setting in global health.Cost effectiveness and resource allocation : C/E · 2018Article
- Application of a Mixed Methods Multi-Criteria Decision Analysis Framework in Integrated Health Care.International journal of integrated careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMulticriteria decision analysis (MCDA) has the potential to bring more structure and transparency to health technology assessment (HTA). The objective of this paper is to highlight key methodological and practical challenges facing the use of MCDA for HTA, with a particular focus on lower and middle-income countries (LMICs), and to highlight potential solutions to these challenges. METHODOLOGICAL CHALLENGES: Key lessons from existing applications of MCDA to HTA are summarized, including: that the socio-technical design of the MCDA reflect the local decision problem; the criteria set properties of additive models are understood and applied; and the alternative approaches for estimating opportunity cost, and the challenges with these approaches are understood. PRACTICAL CHALLENGES: Existing efforts to implement HTA in LMICs suggest a number of lessons that can help overcome the practical challenges facing the implementation of MCDA in LMICs, including: adapting inputs from other settings and from expert opinion; investing in technical capacity; embedding the MCDA in the decision-making process; and ensuring that the MCDA design reflects local cultural and social factors.
conclusionMCDA has the potential to improve decision making in LMICs. For this potential to be achieved, it is important that the lessons from existing applications of MCDA are learned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.